LLY

RED FLAG: ABSENT

No signs of fatal stress emerge on liquidity, leverage, or governance. Debt/EBITDA stands around 0.88x with cash and liquid investments of about $7.3B. The main risk profile is linked to growth expectations, GLP-1 drug pricing, and commercial execution, not to the company’s financial survival.

AI DISRUPTION RISK: LOW

For a big pharma company whose business is based on patents, regulatory approvals, and large-scale production capacity, artificial intelligence is an accelerator of R&D and trial design, not a threat to the core business model.

B1.1 — Leadership and systemic role: 9.50

Eli Lilly currently holds a global leadership position in the most dynamic axis of pharma: the GLP-1 market for diabetes and obesity. With Mounjaro and Zepbound, it effectively forms a duopoly with Novo Nordisk in a segment where demand is structurally above supply. In Q4 2025, revenue reached $19.3B (+43% year over year), with FY2026 guidance of $80–83B. Its systemic role in the obesity treatment chain — involving physicians, payers, healthcare systems, and hospitals — is now consolidated and difficult to erode in the short term.

B1.2 — Customers and barriers to entry: 9.00

Competitive barriers are among the highest in the entire industrial universe: multi-year patents on key molecules, R&D and clinical trial costs in the billions of dollars, FDA regulatory complexity, industrial-scale production infrastructure for injectable drugs, and established relationships with major payers and healthcare systems. The advantage is not only scientific but also logistical and distributive, with production ramp-up capacity that few competitors can replicate.

B1.3 — Business economics: 9.25

The economic quality of the business is of rare caliber. FY2025: revenue $65.18B (+44.7%), net income $20.64B (+94.9%), operating margin 46.59%, ROIC above 30%. Pricing power on the GLP-1 portfolio remains high despite growing pressure on rebates. The ability to reinvest generated cash flows into R&D and production capacity — without compromising current profitability — distinguishes Lilly from traditional sector peers.

B1.4 — Balance sheet and resilience: 8.00

The balance sheet is solid but not without elements to monitor. Total debt stands around $42.5B, offset by very high EBITDA (debt/EBITDA ~0.88x) and a liquid position of about $7.3B. Operating resilience is high, but the extraordinary capex needs required to expand GLP-1 production capacity and management of working capital/inventory deserve attention in coming quarters. The balance sheet is not a structural weakness, but neither is it in the category of an unconditional fortress.

B2.1 — Sector cycle: 6.50

The pharmaceutical sector shows a bifurcated picture in 2026. On the positive side: aggregate earnings revisions on expanding metabolic therapies, GLP-1 demand structurally above production supply, and zero credit stress for large caps. On the negative side: regulatory headwinds in the US on drug pricing (IRA and political pressure), imminent patent cliffs for several groups in the sector, and obesity TAM growth estimates revised downward compared with the peaks of enthusiasm of 2024–2025. With 3/5 objective factors in positive territory, the sector cycle is overall supportive, but not a full and uniform tailwind.

B2.2 — Structural trends: 8.00

Long-term drivers remain among the strongest in the investable universe. Global demographic aging, the increase in chronic lifestyle-related diseases, expansion of the obesity TAM, and progress in incretin biology create a secular tailwind. The only note of caution compared with the previous two-year period is that the most aggressive growth estimates have been at least partially scaled back, and the market already prices in a scenario of sustained expansion: the margin for positive surprise has narrowed.

B2.3 — Competitive positioning in the cycle: 9.25

Within this sector context, Lilly is structurally positioned better than average. While many traditional peers face patent cliffs and weak growth, Lilly is expanding margins, increasing market share, and leading clinical innovation. New data on retatrutide (superior efficacy in reducing glycemia and weight in diabetes, March 2026) further strengthens the medium-term competitive profile. The combination of current leadership and an advancing pipeline is difficult to replicate in the short term.

B2.4 — Exogenous risks: 6.50

Exogenous risks are real and not negligible, though they do not create binary scenarios. The main one is political and regulatory pressure on pricing in the US — with the TrumpRx initiative highlighting the wide pricing gap versus other markets — which could accelerate government negotiation over obesity drugs. Added to this is rising competition in anti-obesity, with new oral entrants (for example Structure Therapeutics) that could erode share in the premium cash-pay segment over the coming years.

B3.1 — Intrinsic Fair Value: 5.00\*

Weighted Fair Value: $1,017.60 (4/4 sources, dispersion 90.2% MIXED, penalty −0.50)

At a price of $921.08, the stock trades at a 9.5% discount to Weighted Fair Value, which falls within the Fair Value range (±9.99%) → base score 5.50. The penalty for mixed dispersion above 60% brings the score to 5.00. Dispersion is very high and, above all, mixed in direction: ValueInvesting ($747.07) and Alpha Spread ($613.13) indicate overvaluation versus the current price, while GuruFocus ($1,266.04) and Simply Wall St ($1,444.16) signal significant undervaluation. In this context, Weighted Fair Value is an indicative reference, not a prescriptive one.

(★) Methodological note: with Business Score ≥ 8.50, standard DCF models tend to structurally underestimate the value of the moat and embedded growth options. Weighted Fair Value is a reference point, not a definitive estimate of value.

B3.2 — Analyst consensus: 8.50

Sell-side consensus remains solidly constructive: average target of $1,209.34 across about 31 analysts, with a prevailing BUY orientation and implied upside of about +31% from the reference price. The target range is wide ($850–$1,500), a sign that estimate dispersion is not limited to DCF models but also appears in analyst valuations. Consensus strength and the size of the implied upside justify a high score, discounted from the maximum because of the wide range.

B3.3 — Relative valuation: 3.75

The 40.14x P/E TTM presents a mixed picture: on one hand it is significantly below Lilly’s 5-year historical average (historically around 60–70x during the re-rating years), on the other it remains structurally above the average of pharmaceutical peers (~18.5x). The AND condition for a high score (multiple < 5y history AND < peers) is not met. The gap versus peers (+117%) is highly material and represents a source of multiple compression if growth slows or expectations are revised downward.

B3.4 — FCF & Net Shareholder Yield: 3.50

FCF TTM: $5.96B | Market Cap: $823.5B

FCF Yield: 0.72% | Dividend Yield: 0.75% | Buyback Yield: ~0.50%

Net Shareholder Yield: ~1.97% → 0–2% range → base score 3.50

Direct cash remuneration to shareholders is limited: free cash flow is real but is absorbed by heavy reinvestment in R&D, production capex, and GLP-1 capacity. This is not a structural weakness of the business, but an allocation choice coherent with the current growth phase. Structurally low Net SY is the implicit cost of extraordinary growth.

(Price Score: average of items B3.1–B3.3: 5.75; average including B3.4: 5.19)

Combined profile: very high-quality business with still favorable outlook, fair valuation.

Competitive Advantage and Moat

The main moat is the combination of intellectual property, regulatory and productive scale, and clinical-commercial leadership in the GLP-1 franchise. The moat is expanding: the active pipeline (retatrutide, orforglipron, Kisunla) continues to produce positive data that broadens the defendable perimeter. The duopoly position with Novo Nordisk in the most dynamic market of the pharmaceutical decade constitutes a barrier to entry that requires billions of dollars and years of clinical trials to replicate.

General Cycle and Competitive Dynamics

The broad pharmaceutical cycle is mixed in 2026, while the obesity/metabolic subsegment is still expanding but with competitive dynamics becoming more complex. Lilly’s advantage within the cycle is clear versus traditional peers: while many face patent cliffs, Lilly is expanding. The medium-term challenge is not defending the current position, but demonstrating that growth can remain above the already elevated expectations embedded in the price.

Catalysts and Future Opportunities (Bull Case)

Main catalysts include: further penetration of Zepbound and Mounjaro in developed and emerging markets, progress of orforglipron (oral GLP-1 pill) as a potential expansion of the TAM toward patients averse to injections, new positive data on retatrutide (significant reduction in glycemia and weight in diabetes, March 2026), and the possibility of maintaining or exceeding FY2026 guidance of $80–83B. If earnings growth remains above 30% annually, multiple re-rating is plausible.

Risks (Bear Case)

Main risks are: compression of prices and rebates on GLP-1 drugs from US government intervention, growing competition from oral formulations (Structure Therapeutics and others), possible disappointment on individual pipeline trials with disproportionate impact on the stock given the elevated valuation, very wide dispersion of fair value models making it difficult to identify a clear margin of safety, and working capital/inventory management that could generate negative operational surprises in coming quarters.

Solid business, fair valuation. Limited opportunity at the current price. NEUTRAL.

Why it could be an opportunity

Eli Lilly presents one of the highest-quality fundamental profiles in the investable universe: rare market leadership, expanding moat, and earnings growth well above the sector. The current price ($921.08) is about 19% below the 52-week highs, and Weighted Fair Value ($1,017.60) is above the market price. Sell-side consensus is solidly constructive with implied upside of 31% toward the average analyst target ($1,209.34). For investors with a 3–5 year horizon, the fundamental profile is difficult to challenge.

Why it could be a risk

Recent weakness (-12.5% over the last 15 sessions, with the price close to the low of the range) signals a narrative shift: from “infinite runway” to the issue of pricing sustainability and cash-pay demand. Dispersion in fair value models (90%) is too high to define the current price as a clear buying opportunity. The P/E multiple remains much higher than that of traditional peers (+117%), leaving the stock vulnerable to downward revisions in growth estimates. The risk/reward asymmetry at the current price is not favorable in the short term.

This analysis is produced by the Score³ system for informational purposes only and does not constitute financial advice, a solicitation to invest, or a trading or investment recommendation. Data is collected from public sources and may contain errors or delays. Fair value estimates and price targets are model-based projections subject to significant uncertainty and do not represent certain forecasts. Investing involves risks, including the possible loss of invested capital. Always verify critical data against primary sources before making any investment decision. Past performance is not indicative of future results.